Phase 1 EGFR Clinical Trials
26 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 26 trials
Recruiting
Phase 1Phase 2
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 1Phase 2
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Metastatic Solid TumorLocally Advanced Solid TumorEGFR Overexpression
Yuhan Corporation80 enrolled4 locationsNCT06975410
Recruiting
Phase 1
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Brain TumorBrain CancerGlioblastoma+4 more
Northwell Health33 enrolled1 locationNCT02861898
Recruiting
Phase 1Phase 2
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805
Recruiting
Phase 1Phase 2
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Non-small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament345 enrolled24 locationsNCT06043817
Recruiting
Phase 1
Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC
EGFR Mutation-positive NSCLC
AstraZeneca12 enrolled3 locationsNCT07500987
Recruiting
Phase 1
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NeuroblastomaNasopharyngeal CarcinomaRhabdomyosarcoma+7 more
Sun Yat-sen University51 enrolled1 locationNCT07584499
Recruiting
Phase 1
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more
ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992
Recruiting
Phase 1
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor MalignanciesEGFREGFR Positive Solid Tumors
Vir Biotechnology, Inc.450 enrolled4 locationsNCT06960395
Recruiting
Phase 1
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ovarian CancerEndometrial CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc.226 enrolled12 locationsNCT07444814
Not Yet Recruiting
Phase 1
A Study of the Safety, Pharmacokinetics and Exploratory Efficacy of RC220 in Combination with Osimertinib in Adult Patients with Non- Small Cell Lung Cancer.
Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations
Racura Oncology Ltd.40 enrolled1 locationACTRN12626000325303
Recruiting
Phase 1
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 1Phase 2
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
EGFR Inhibitor-associated Rash
Azitra Inc.32 enrolled6 locationsNCT06830863
Recruiting
Phase 1
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc.18 enrolled3 locationsNCT07315113
Recruiting
Phase 1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Advanced Solid TumorCancerNSCLC+5 more
TOLREMO therapeutics AG50 enrolled7 locationsNCT06403436
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 1
HER-2 B Cell Peptide Vaccine
Metastatic Breast CancerHER2-positive Breast CancerMetastatic Gastrointestinal Carcinoma+2 more
Pravin T.P Kaumaya42 enrolled1 locationNCT06414733
Recruiting
Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Colorectal, CancerSquamous Cell Carcinoma of Head and NeckHead and Neck Squamous Cell Carcinoma+8 more
Bicara Therapeutics292 enrolled20 locationsNCT04429542